US breakthrough designation for ligelizumab in chronic spontaneous urticaria unresponsive to H1-antihistamine treatment

Ligelizumab is a monoclonal antibody that is thought to work by blocking the IgE/FcεRI pathway, which plays a key role in the inflammatory process in chronic spontaneous urticaria. It is being compared to omalizumab in ongoing Phase III clinical trial programmes.

PharmaTimes